2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P991132
    Efclarofusp alfa 3053638-35-7 98%
    Efclarofusp alfa is a CHO-expressed humanized antibody consisting of VEGFR-1 and VEGFR-2 regions fused to human IgG1 Fc. Efclarofusp alfa is an angiogenesis inhibitor.
    Efclarofusp alfa
  • HY-P991133
    Efranarelaxin alfa 2969217-22-7 98%
    Efranarelaxin alfa is a relaxin receptor agonist. Efranarelaxin alfa is promising for research of cardiovascular diseases and tissue repair.
    Efranarelaxin alfa
  • HY-P991169
    Zemocimig 2955620-21-8 98%
    Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
    Zemocimig
  • HY-P991210
    Efzimfotase alfa 2746354-58-3 98%
    Efzimfotase alfa (ALXN-1850) is enzyme replacement therapy agent targeting the deficiency of tissue-nonspecific alkaline phosphatase (TNSALP). Efzimfotase alfa functions by hydrolyzing the substrates of TNSALP, reducing the concentrations of substrates such as inorganic pyrophosphate (PPi) and pyridoxal 5′-phosphate (PLP). Efzimfotase alfa is promising for research of hypophosphatasia (HPP).
    Efzimfotase alfa
  • HY-P991211
    Bemiltenase alfa 2766038-73-5 98%
    Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia.
    Bemiltenase alfa
  • HY-P991213
    Nonacog gamma 98%
    Nonacog gamma is a coagulation factor IX (FIX) supplement. Nonacog gamma activates coagulation factor X (FX), promotes the generation of thrombin, and then converts fibrinogen into fibrin, forming a stable blood clot to exert hemostatic activity. Nonacog gamma is promising for research of hemophilia B.
    Nonacog gamma
  • HY-P991340
    CT140 98%
    CT140 is a human IgG4 monoclonal antibody (mAb) targeting PAI-1. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
    CT140
  • HY-P991412
    NI-301 98%
    NI-301 is a human monoclonal antibody (mAb) targeting Transthyretin/TTR. NI-301 can be used in Cardiomyopathies and Familial amyloid neuropathy research.
    NI-301
  • HY-P991474
    TATX-21 98%
    TATX-21 is a human monoclonal antibody (mAb) targeting ACVRL1/ALK-1. TATX-21 can be used in arterial sclerosis and heart disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    TATX-21
  • HY-P991516
    TB-402 98%
    TB-402, a human IgG4 anticoagulant monoclonal antibody, is a partial Factor VIII inhibitor. TB-402 has a prolonged antithrombotic effect. TB-402 can be used for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR).
    TB-402
  • HY-P991539
    CM101 2244739-55-5 98%
    CM101 is an anti-pathoangiogenic polysaccharide that can be derived from group B streptococcus. CM101 can inhibit inflammatory angiogenesis and accelerate wound healing in mouse models as well as minimizing scarring after spinal cord injury. CM101 also causes rapid tumor neovascularitis, infiltration of inflammatory cells, inhibition of tumor growth and tumor apoptosis.
    CM101
  • HY-P991574
    MEDI-5884 2643310-75-0 98%
    MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonal antibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research.
    MEDI-5884
  • HY-P991579
    REGN-9933 98%
    REGN-9933 is a humanized monoclonal antibody inhibitor targeting FXI. REGN-9933 can be used for atherothrombosis and venous thromboembolism research.
    REGN-9933
  • HY-P991580
    REGN-7508 98%
    REGN-7508 is a humanized monoclonal antibody inhibitor targeting FXI. REGN-7508 can be used for atherothrombosis and venous thromboembolism research.
    REGN-7508
  • HY-P991581
    MK-2060 2812480-88-7 98%
    MK-2060 is a humanized monoclonal antibody inhibitor targeting FXI. MK-2060 can be used for atherothrombosis and venous thromboembolism research.
    MK-2060
  • HY-P991657
    MEDI7814 98%
    MEDI7814 is a humanized monoclonal antibody inhibitor targeting C5a and C5adesArg. MEDI7814 binds to recombinant human C5a and serum purified human C5a with affinities of 14 pM and 8 pM, respectively. MEDI7814 is acute inflammatory diseases such as sepsis and renal ischemia-reperfusion injury.
    MEDI7814
  • HY-P991667
    NKTT120 98%
    NKTT 120 is a humanized monoclonal antibody against the iNKT cells. NKTT 120 is promising for research of sickle cell disease (SCD).
    NKTT120
  • HY-P991677
    Efmirenpase alfa 2770242-54-9 98%
    Efmirenpase alfa is an Fc-ENPP1 fusion protein (human IgG1 Fc domain linked to a modified human ENPP1). Efmirenpase alfa has prolonged half-life and enhanced receptor affinity compared with native human ENPP1. Efmirenpase alfa can be used as an enzyme replacement therapy for ENPP1 deficiency such as arterial calcification and hypophosphatemic rickets research.
    Efmirenpase alfa
  • HY-P991694
    Latarcibart 3036400-21-9 98%
    Latarcibart is a humanized IgG4κ antibody targeting Protein S/PROS1. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003).
    Latarcibart
  • HY-P991721
    Ticalicibart 3033317-31-3 98%
    Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research.
    Ticalicibart
Cat. No. Product Name / Synonyms Application Reactivity